WO2026012311 - FGF21 DERIVATIVE AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/012311
Publication Date
15.01.2026
International Application No.
PCT/CN2025/107293
International Filing Date
07.07.2025
Title **
[English]
FGF21 DERIVATIVE AND USE THEREOF
[French]
DÉRIVÉ DE FGF21 ET SON UTILISATION
[Chinese]
FGF21衍生物及其用途
Applicants **
ZHEJIANG DOER BIOLOGICS CO., LTD.
Inventors
CHEN, Yonglu
LI, Teng
YAO, Gaofeng
HUANG, Yanshan
ZHOU, Zhenxing
Priority Data
202410904804.8
08.07.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2305 | |
| EPO | Filing, Examination, Granting | 18970 | |
| Japan | Filing, Examination, Granting | 2577 | |
| South Korea | Filing, Examination, Granting | 2820 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
32,812
Abstract[English]
A long-acting FGF21 derivative, specifically relating to an FGF21 derivative comprising an FGF21 mutant protein and a fatty acid chain. The FGF21 derivative, which is obtained by coupling the fatty acid chain to a cysteine residue at position 172 of an FGF21 protein by means of a linker, has relatively high FGF21 activity, and has a better weight loss effect in model mice. The FGF21 mutant protein not only retains the activity of mature FGF21, but also has significantly improved stability in serum.[French]
L'invention concerne un dérivé de FGF21 à action prolongée, en particulier, un dérivé de FGF21 comprenant une protéine mutante FGF21 et une chaîne d'acides gras. Le dérivé de FGF21, qui est obtenu par couplage de la chaîne d'acides gras à un résidu cystéine en position 172 d'une protéine FGF21 au moyen d'un lieur, présente une activité FGF21 relativement élevée, et présente un meilleur effet de perte de poids chez des souris modèles. La protéine mutante FGF21 conserve non seulement l'activité du FGF21 mature, mais présente également une stabilité significativement améliorée dans le sérum.[Chinese]
一种长效FGF21衍生物，具体涉及一种包含FGF21突变体蛋白和脂肪酸链的FGF21衍生物，脂肪酸链通过连接体偶联至FGF21蛋白的172位置的半胱氨酸残基，获得的FGF21衍生物具有较高的FGF21活性，且在模型小鼠体内减重效果较佳。一种FGF21突变体蛋白，不仅保留了成熟FGF21的活性，而且在血清中的稳定性显著提高。